ATRYS HEALTH, S.A. | Sales 2024 * | 223M 239M 19.91B | Sales 2025 * | 240M 257M 21.41B | Capitalization | 219M 234M 19.55B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 8M 8.57M 715M | EV / Sales 2024 * | 1.68 x |
| Net Debt 2024 * | 155M 166M 13.88B | Net Debt 2025 * | 121M 130M 10.82B | EV / Sales 2025 * | 1.42 x |
| P/E ratio 2024 * |
-66.8
x | P/E ratio 2025 * |
25
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 13/07/13 | |
| Director of Finance/CFO | - | 01/15/01 | |
| Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 01/16/01 | |
| Director/Board Member | 69 | - | |
| Director/Board Member | - | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.89% | 84.68B | |
| +14.90% | 81.12B | |
| +10.49% | 29.59B | |
| -10.21% | 16.73B | |
| -1.39% | 16.36B | |
| -31.58% | 11.77B | |
| +1.82% | 11.72B | |
| +31.40% | 11.71B | |
| -0.47% | 11.66B |
